Whitehawk Therapeutics Stock Rockets on AI Partnership

16 October 2025

Stock jump: WHWK shares surged on Oct. 16, 2025 after announcing a collaboration with Tempus AI ^[1]. Investing.com reported the stock “surged 67%” on the news ^[2].
Recent prices: WHWK closed Oct. 15 at about $2.10 (up ~6.6% that day) ^[3] ^[4]. Early on Oct. 16 it was trading well above $3.00, reflecting the pre-market rally.
Tempus deal: The deal is a “multi-year collaboration” leveraging Tempus’s real-world patient data and AI tools to refine Whitehawk’s cancer trials ^[5]. Whitehawk’s CEO Dave Lennon said the partnership will guide their programs “by data-driven insights” ^[6].
Pipeline focus: Whitehawk is developing antibody-drug conjugates (ADCs) targeting PTK7, MUC16 and SEZ6 in solid tumors ^[7] ^[8]. The company plans IND filings for its lead ADCs (HWK-007 and HWK-016) by year-end 2025 ^[9]. (These ADCs attach potent drugs to antibodies, a cutting‑edge precision cancer strategy.)
Financials: In Q2 (June 30) 2025, Whitehawk lost $0.76 per share, missing estimates ^[10]. It reported ~$177.2M in cash on hand, up from $47.2M a year earlier, and says this will fund operations into 2028 ^[11].
Analyst view: Few analysts cover WHWK. As of early Oct., the consensus rating was “reduce” (more sellers than buyers) ^[12]. Zacks recently upgraded WHWK to a “Hold,” but Weiss Ratings and others still view it skeptically ^[13]. Price targets are in the low-$2 range.
Industry trend: ADCs are a hot area in oncology. Leading ADCs (e.g. AstraZeneca’s Enhertu) now sell for multibillion annual revenues ^[14]. Major pharma like Boehringer Ingelheim are rapidly expanding their ADC pipelines ^[15]. A recent report noted a flood of new conjugated cancer drugs (436 added in 2024/25) ^[16]. Whitehawk’s AI-focused partnership taps this trend toward precision, biomarker-driven cancer therapies.

Whitehawk’s stock popped dramatically on Oct. 16 after news of the Tempus collaboration. Shares had been around $2 per share in mid-October ^[17], but the new AI partnership sent them soaring in early trading. By mid-day Oct. 16, various data sites showed WHWK up roughly 50–67% on the session ^[18]. (For comparison, it had already gained ~6.6% on Oct. 15 ^[19] ^[20].) The sudden jump reflects investor excitement about the Tempus deal, which was announced in a press release on Oct. 16 ^[21].

The Tempus AI collaboration was officially billed as a “multi-year” partnership to use Tempus’s de-identified, multimodal clinical data to improve Whitehawk’s ADC drug development ^[22]. In practice, this means Whitehawk will apply Tempus’s large real-world patient database and AI analytics to design smarter clinical trials and identify the patients most likely to benefit from its ADCs ^[23] ^[24]. Tempus’s COO, Ryan Fukushima, said that pairing “Tempus’ comprehensive, multimodal data” with Whitehawk’s ADC expertise creates “a powerful foundation” for validating Whitehawk’s cancer targets ^[25]. Whitehawk’s CEO, Dr. Dave Lennon, added that the goal is to “better understand the expression of our ADC protein targets” using data-driven insights to prioritize which cancers to target first ^[26]. In other words, instead of relying solely on lab tests of tumor samples (IHC), the partnership will use large-scale RNA and clinical data to find where the targets PTK7, MUC16, SEZ6 are most relevant, potentially speeding patient recruitment and approval.

Whitehawk’s pipeline is focused on ADCs in development. Its website notes three ADC assets in-licensed from WuXi Biologics, intended to reach the clinic soon ^[27]. The lead candidates, HWK-007 (targeting PTK7) and HWK-016 (targeting MUC16), are slated to file INDs by the end of 2025 ^[28] ^[29]. The third asset, HWK-206 (targeting SEZ6), is planned for IND by mid-2026 ^[30]. Management emphasizes that these targets are “clinically validated” proteins with high expression in lung, gynecologic, and neuroendocrine cancers ^[31] ^[32]. By leveraging Tempus data, Whitehawk hopes to confirm which tumors have the highest unmet need and best match these ADCs.

On the financial side, Whitehawk remains pre-revenue and cash-burning. In the Aug 7 Q2 report, it disclosed a net loss of $52.6M for the quarter (about $0.76 per share), compared to a much smaller loss a year earlier ^[33]. This included a ~$38M upfront payment to WuXi for the ADC rights, which inflates the loss. Importantly, Whitehawk had a strong cash position: $177.2M on hand as of June 30, 2025, up from $47.2M a year prior ^[34]. Management says that at current spending plans, this cash should fund operations into 2028 ^[35], through initial clinical trials of the ADCs. In practice, that means Whitehawk is unlikely to need a stock-dilutive financing anytime soon – a rare comfort for a small biotech – because it raised a large funds earlier in 2024.

Despite the recent stock spike, Wall Street experts remain cautious. There are few analyst reports: MarketBeat notes only two recent firms covering WHWK ^[36]. Most have rated it at “Hold” or “Sell” (consensus is a “Reduce”) ^[37]. For example, Zacks upgraded WHWK to a hold in early October, while Weiss Ratings still assigns a sell rating ^[38]. Price targets from analysts are modest (around $2–$3), reflecting the company’s early stage. One reason for conservatism is that the stock is very small – market cap was only about $100–101M in early Oct. ^[39] ^[40]. That cap is now higher after the rally, but it still compares to tens of billions for successful ADC companies. In short, some analysts might view WHWK as undervalued on its cash and pipeline, but others warn it has a history of large losses and must prove its science in clinic.

Industry context: Whitehawk’s news taps into broader biotech trends. ADCs have become a blockbuster area of cancer drug development. As BioPharma Dive recently noted, ADCs are “one of the most popular areas of cancer research,” driven by successes like AstraZeneca’s Enhertu (trastuzumab deruxtecan) which earned about $3.8 billion in 2024 ^[41]. Virtually all large pharma now has ADC programs: for example, on Oct. 15 Boehringer Ingelheim announced it was licensing a new ADC from Korea’s AimedBio, saying ADCs combine “biological precision with chemical potency” against cancer ^[42]. A market report counted 436 new “conjugated” cancer drugs (mostly ADCs and related formats) added to pipelines in 2024/25 ^[43]. Investors see big value if even one new ADC proves successful.

Overall, Whitehawk’s Tempus deal and resulting stock pop illustrate how data-driven oncology is in focus. The collaboration promises to sharpen Whitehawk’s ADC programs with AI and real-world insights – a strategy many in the industry are pursuing. However, the company still needs to demonstrate clinical wins (e.g. safety/efficacy of HWK-007/016) to justify its valuation. For now, analysts will be watching upcoming trial starts and any new data closely. The October run-up shows sentiment can swing fast on good news, but most professional models will wait for hard clinical milestones before moving off the sidelines ^[44] ^[45].

Sources: Whitehawk Therapeutics/Tempus press releases ^[46] ^[47] ^[48]; stock news and financial data ^[49] ^[50] ^[51] ^[52]; industry reports ^[53] ^[54] ^[55] ^[56]. All quoted data is as of Oct. 16, 2025.

18 Minutes Whitehawk Limited

Watch this video on YouTube.

References

Tags:

Marcin Frąckiewicz Latest posts

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

View all

AMD’s AI Mega-Deal Sparks Stock Surge – Inside the OpenAI Partnership, New Chips & Showdown with Rivals

16 October 2025

Regional banks tumble as sour loans spark concerns; Jefferies, Zions in focus
October 16, 2025, 3:48 PM EDT. Regional bank stocks declined as fears about sour loans and looser private-credit risks spiked. Zions disclosed a sizable charge on bad loans, and Western Alliance faced a fraud allegation, roiling investors despite guidance reiterations. The weakness extended to Jefferies, whose exposure to First Brands and Tricolor Holdings helped weigh on the shares as hedge funds are owed hundreds of millions. The auto-sector bankruptcies fueling scrutiny of private credit have investors worried about a broader loan-quality spell. Analysts cautioned that a few credit-one-offs can spark quick selling, even if the hits appear contained. JPMorgan's Jamie Dimon warned that, in this environment, 'cockroaches' in credit may multiply, underscoring risk-off sentiment across markets.
SMCI Stock Price Forecast: Super Micro Targets $70 as AI Revenue Surges to $21.97B
October 16, 2025, 3:46 PM EDT. Super Micro Computer (SMCI) is at the center of the AI hardware boom, with AI hardware revenue reaching $21.97B in FY2025, up 47% YoY, and Q4 sales of $5.76B. About 70% of Q4 revenue came from AI platform systems, signaling a shift to high-density, rack-scale deployments with NVIDIA GPUs. Management targets FY2026 revenue of at least $33B, implying ~45% growth as hyperscalers deploy compute. Yet margins compress: gross margin at 9.6% (non-GAAP) and operating margin around 3.97%, with profitability lagging peers. Valuation shows a disconnect: EV/Revenue and P/S below peers. Analysts model FY2026 EPS ~$2.58 and FY2027 ~$3.45, supporting a bull case around a $70 target (≈1.3x forward P/S). Balance sheet remains solid with cash ≈$5.18B and debt ≈$5.06B.
Gita Gopinath warns US equities reliance could deepen impact of next market crash
October 16, 2025, 3:36 PM EDT. Former IMF chief economist Gita Gopinath warns that the reliance on US equities-fueled by AI optimism-risks amplifying the next market downturn. The rally, near an all-time high amid tariff tensions and global policy headwinds, could set the stage for a painful correction larger than the dotcom crash. She projects American households could lose over $20 trillion in wealth, equivalent to about 70% of US GDP in 2024, while foreign investors could see losses exceeding $15 trillion (roughly 20% of the rest of the world's GDP). The decline in the dollar's flight to safety cushion and doubts about the Fed's independence could further erode confidence in US financial assets. Tariffs, China's mineral controls, and geopolitical risks create a fragile backdrop with limited policy tools to soften any downturn and threaten global trade.
Collar Capital Bets on Salesforce (CRM) With 14,161-Share Purchase
October 16, 2025, 3:35 PM EDT. Collar Capital Management LLC disclosed a new position in Salesforce (CRM), buying 14,161 shares valued at roughly $3.36 million as of September 30, 2025. The trade represents about 2.36% of the fund's AUM ($142.14 million in reportable U.S. equity holdings) and expands Collar's footprint to 71 reportable positions. Salesforce shares traded around $236.58 on October 15, 2025, down about 17.95% in the past year and lagging the S&P 500 by roughly 32.23 percentage points. The move arrives as Collar's pipeline shows top bets in other high-profile tech names such as MSTR, TSLA, MU, COIN, and AAPL.
Turning a Portfolio into a Retirement Paycheck: Stock Advisor, the 4% Rule, and Forgotten 401(k)s
October 16, 2025, 3:34 PM EDT. In this Motley Fool Money podcast, retirement expert Robert Brokamp talks with David Blanchett about turning a portfolio into a steady retirement paycheck and why many retirees could spend more than they realize. They cover where to invest $1,000 today, and why Stock Advisor's top stocks may help, with Stock Advisor's track record cited. The discussion also explores whether the 4% withdrawal rate is too low, how the federal shutdown could delay key data, the risk of IRA theft, rising CPI components, and the roughly $2.1 trillion in forgotten 401(k)s and how to recover them. A full transcript is included, and the episode highlights actionable ideas to improve retirement outcomes.

Whitehawk Therapeutics Stock Rockets on AI Partnership – What Investors Need to Know

References

Tags:

Related Articles

AMD Stock Skyrockets on AI Mega-Deals — Is $300 Next?

Palantir Stock Skyrockets Again – AI Boom Sparks 300% 2025 Rally (Is a Correction Coming?)

Agnico Eagle Mines Stock Soars to New Highs — Gold Boom Fuels Bullish Outlook

Polestar Stock Skyrockets on Strong EV Sales and New Tech – What’s Next?

J.B. Hunt (JBHT) Stock Soars on Earnings Surprise – Is a Freight Sector Revival Underway?

Stock Market Today